AbbVie Wins FDA Approval for First D1/D5 Parkinson's Drug JUVMO
North Chicago, Ill. – – September 28, 2026 -- AbbVie (NYSE: ABBV) has secured U.S. FDA approval for JUVMO (tavapadon), the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, with commercial availability set for October 2026.
JUVMO targets dopamine pathways differently than existing D2/D3 agonists
Roopal Thakkar, AbbVie's chief scientific officer, called the approval the first dopaminergic breakthrough for Parkinson's disease in decades. The once-daily oral tablet can be taken with or without levodopa, positioning it across the full disease continuum rather than a single treatment stage.